Lilly to cut insulin prices by 70%, cap costs at $35 per month for people with private insurance
The announcement comes amid growing federal pressure to lower the cost of insulin prices.
Hacked Washington law firm fights SEC subpoena in effort to protect attorney-client privilege
Covington & Burling is fighting to protect client names from the SEC, in a case that could significantly impact the nature of attorney-client relationships
Op-ed: Offshoring crypto hurts the financial system and America’s geopolitical standing, says Coinbase CEO Brian Armstrong
The U.S. has the opportunity to lead in crypto and reap the benefits, writes Coinbase CEO Brian Armstrong.
JPMorgan downgrades Marqeta, cites muted 2023 growth outlook for the payments company
JPMorgan lowered its rating for Marqeta to neutral from overweight. It also slashed its price target to $6 from $9.
Mortgage demand from homebuyers drops to a 28-year low
Mortgage demand dropped for the third straight week as interest rates moved higher again.
Morgan Stanley upgrades Sarepta Therapeutics, says biotech stock can rally more than 50%
Morgan Stanley upgraded Sarepta shares to overweight, saying that the path for SRP-9001 appears “de-risked.”
UBS upgrades Procter & Gamble, says household goods giant can rally nearly 20%
Analyst Peter Grom says despite the company’s recent underperformance, an “earnings inflection” and margin expansion are on the horizon for the company.
Lori Lightfoot becomes the first Chicago mayor in 40 years to lose re-election
The embattled Democrat, who has been dogged by persistent crime in the city, failed to get enough votes to advance to an April runoff election.
FBI director accuses China of trying to ‘thwart and obfuscate’ Covid origin probe
“The FBI has for quite some time now assessed that the origins of the pandemic were most likely a potential lab incident in Wuhan,” Wray said in an interview Tuesday.
FDA advisors recommend first-ever RSV vaccine from Pfizer, despite possible Guillain-Barre risks
Several FDA advisors said there could be a significant safety issue after two vaccine recipients out of about 20,000 developed Guillain-Barre syndrome.
